AETERNUSPERFORMANCEJoin

CJC-1295 no DAC

CJC-1295 no DAC is a modified GHRH(1-29) discussion topic centered on GH-axis signaling, pulse-oriented research, and DAC distinction.

Evidence level
Early human data
Human studies
2
Total sources
5
Last reviewed
2026-06-03

Reviewed by Bryan Powell · editorial review, not medical review

GHRH signaling · GH axis · DAC distinction

At a glance

CJC-1295 no DAC is a growth-hormone-axis topic that needs careful naming from the start. It is commonly discussed as modified GRF 1-29, a short GHRH-fragment analog, while much of the indexed CJC-1295 human literature involves the DAC-conjugated long-acting compound. A useful profile should explain the GHRH biology while making that evidence boundary visible.

What CJC-1295 no DAC is

CJC-1295 no DAC is commonly used in public discussion to describe a modified version of the active GHRH(1-29) fragment without the drug-affinity complex used in CJC-1295 DAC. That distinction matters because the no-DAC and DAC forms are not the same pharmacology story. The no-DAC discussion is usually about shorter, pulse-oriented GHRH signaling, while the DAC literature concerns longer exposure through albumin-binding pharmacology.

Mechanism

Why It Shows Up in Growth Hormone Axis Discussions

The biological context centers on hypothalamic-pituitary signaling, GHRH receptor activity, GH pulsatility, and downstream IGF-1 context. Those systems are endocrine systems, not casual performance levers. The key public-facing point is that GH-axis signaling can be biologically important without becoming a validated body-composition, recovery, sleep, or longevity claim.

Modified GHRH Biology, Without Borrowing DAC Claims

CJC-1295 no DAC is best explained through GHRH receptor signaling. GHRH analogs act at pituitary somatotroph pathways that regulate growth hormone release, and the GRF(1-29) platform literature helps explain why short GHRH fragments became pharmacology tools. The no-DAC form should be described as a modified GHRH-fragment discussion, not as interchangeable with the DAC investigational compound.

The direct human CJC-1295 papers are useful but mostly point to DAC CJC-1295. Those studies support discussion of the GH and IGF-1 axis, pulsatility, and long-acting pharmacology, but they do not directly validate no-DAC outcomes. The responsible mechanism language is therefore layered: GHRH biology is well established, DAC CJC-1295 has human pharmacology data, and no-DAC public claims should remain much more conservative.

What the evidence actually shows

Human data

Direct human trial evidence among the reviewed sources.

The reviewed sources include human CJC-1295 clinical pharmacology, but those direct human sources primarily concern the DAC-conjugated form rather than CJC-1295 no DAC. Human-facing no-DAC language should therefore remain limited and should not imply validated body-composition, recovery, sleep, or endocrine optimization outcomes.

Preclinical data

Animal or in-vitro work. Does not establish human effect.

The mechanistic evidence is strongest at the GHRH analog and GRF(1-29) platform level, including animal and pharmacology work around receptor activation and long-acting analog design. This supports biological plausibility and naming context, not direct no-DAC clinical translation.

Anecdotal discussion

Reported experience. Not evidence of effect.

Anecdotal discussion around CJC-1295 no DAC often focuses on GH pulse language, pairing with ghrelin-receptor secretagogues, and anti-aging or recovery expectations. That discussion can explain why the entry is visible, but it cannot establish product identity, safety, timing logic, or outcomes.

Where people overreach

No-DAC evidence is indirect. Much of the named CJC-1295 human literature concerns the DAC form, so no-DAC claims should be treated with restraint.

GH-axis biology is not an outcome promise. Signaling through the pituitary does not validate body-composition, recovery, sleep, or longevity claims.

Nomenclature is a real limitation. Public use of CJC-1295, modified GRF 1-29, no DAC, and DAC terminology can blur distinct pharmacology.

Product identity and safety remain unresolved. Real-world materials may differ from research definitions and regulatory context.

Safety and regulatory context

Regulatory status matters. FDA compounding-risk context for CJC-1295 supports caution around immunogenicity, peptide impurities, and product characterization.

Endocrine context matters. GH-axis signaling can affect multiple downstream systems and should not be presented as a casual wellness lever.

Quality and naming matter. Confusion between no-DAC and DAC forms can lead to claims that do not match the compound being discussed.

Practical interpretation

CJC-1295 no DAC appears in performance and recovery conversations because growth hormone signaling is culturally associated with tissue repair, sleep, body composition, and aging. That public association is exactly where overreach begins. Aeternus treats the compound as an endocrine research topic, not a shortcut or optimization recommendation.

The practical value of this entry is to help readers separate physiology from claims. GHRH can explain why the compound is discussed. DAC clinical pharmacology can explain why the name CJC-1295 appears in the literature. Neither category should be turned into a claim that no-DAC use produces predictable human outcomes.

What CJC-1295 no DAC is not

Not the same as CJC-1295 DAC. No-DAC and DAC forms should not be treated as interchangeable evidence bases.

Not a validated optimization tool. The current evidence does not support assured recovery, body-composition, sleep, or longevity outcomes.

Not a shortcut around fundamentals. Endocrine signaling does not replace training, nutrition, sleep, clinical context, or health status.

Aeternus position

Aeternus views CJC-1295 no DAC as a naming-sensitive endocrine research topic. The useful work is not to make GH-axis signaling sound more exciting; it is to keep the no-DAC and DAC evidence lanes separate. The right position is measured: explain GHRH biology, identify the limits of direct no-DAC evidence, keep regulatory risk visible, and refuse shortcut endocrine claims.

Regulatory status

Three separate questions, kept separate on purpose. Whether CJC-1295 no DAC appears on FDA’s pharmacy-compounding list, whether an approved medicine containing it exists, and whether it is banned in sport are three different things, and the answer to one tells you nothing about the others.

FDA 503A bulk substances list

Could not verify

We could not establish this from a primary source.

Genuinely unresolved. FDA publishes one undifferentiated 'CJC-1295' entry and never uses the name 'modified GRF 1-29'. We cannot confirm from any FDA source whether that entry covers this form, so we state unknown rather than assume either way.

Primary source

Source directness: high — a named primary document states this outright

FDA approval

No FDA-approved product

Primary source

Source directness: high — a named primary document states this outright

WADA prohibited list

Prohibited at all times · S2.2.4 · named explicitly

Prohibition is not in doubt even though the FDA listing is: WADA names CJC-1295, and the GHRH-analogue class wording captures this form independently.

Primary source

Source directness: high — a named primary document states this outright

Verified against primary sources on 2026-07-31

Regulatory status changes, sometimes quickly. This reflects what the primary sources said on the date above and nothing more. Verify before acting on it.

Sources (5)

  1. animal study · moderateHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogEndocrinology, 2005 · doi:10.1210/en.2004-1286
  2. human study · moderateProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJournal of Clinical Endocrinology & Metabolism, 2006 · doi:10.1210/jc.2005-1536
  3. human study · moderatePulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogJournal of Clinical Endocrinology & Metabolism, 2006 · doi:10.1210/jc.2006-1702
  4. regulatory · moderateCJC 1295 Modified GRF (1-29) (same as CJC 1295 w/out DAC)FDA Pharmacy Compounding Advisory Committee material, 2024
  5. regulatory · moderateCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA, 2026

Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.

Other compounds in Hormone & Growth Signaling